Skip to main content
Midas Edge

Armata Pharmaceuticals, Inc.

For the period ended Jun 30, 2026. Filed Aug 12, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 12, 2026

ARMP$3.75-1.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Stockholders’ Deficit

Three and Six Months Ended June 30, 2026 and 2025

(in thousands, except share data)

​​​​​​​​​​​​​​​
​ · ​ · Stockholders’ Deficit
​ · ​ · Common Stock · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​
​ · ​ · ​ · ​ · ​ · ​ · ​ · Additional · ​ · ​ · ​ · Total
​ · ​ · ​ · ​ · ​ · ​ · ​ · Paid-in · ​ · Accumulated · ​ · Stockholders’
​ · ​ ​ ​ · Shares · ​ ​ ​ · Amount · ​ ​ ​ · Capital · ​ ​ ​ · Deficit · ​ ​ ​ · Deficit
Balances, March 31, 202536,193,479​$362​$280,121​$(334,266)​$(53,783)
Stock-based compensation expense—​​—​​575​​—​575
Net loss—​​—​​—​​(16,295)​(16,295)
Balances, June 30, 202536,193,479​$362​$280,696​$(350,561)​$(69,503)
​​​​​​​​​​​​​​​
​​​​​​​​​​​​​​​
​​Stockholders’ Deficit
​​Common Stock​​​​​​​​​
​​​​​​​Additional​​​Total
​​​​​​​Paid-in​Accumulated​Stockholders’
​​Shares​ ​ ​Amount​ ​ ​Capital​ ​ ​Deficit​ ​ ​Deficit
Balances, March 31, 202636,644,703​$366​$304,928​$(616,880)​$(311,586)
Exercise of stock options​163,017​​2​​506​​—​​508
Issuance of common stock under ATM, net​338,000​​3​​2,370​​​​​2,373
Stock-based compensation expense​—​​—​​3,391​​—​​3,391
Net income—​​—​​—​​74,141​​74,141
Balances, June 30, 202637,145,720​$371​$311,195​$(542,739)​$(231,173)
​​​​​​​​​​​​​​​
​ · ​ · Stockholders’ Deficit
​ · ​ · Common Stock · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​
​ · ​ · ​ · ​ · ​ · ​ · ​ · Additional · ​ · ​ · ​ · Total
​ · ​ · ​ · ​ · ​ · ​ · ​ · Paid-in · ​ · Accumulated · ​ · Stockholders’
​ · ​ ​ ​ · Shares · ​ ​ ​ · Amount · ​ ​ ​ · Capital · ​ ​ ​ · Deficit · ​ ​ ​ · Deficit
Balances, December 31, 202436,183,067​$362​$279,354​$(327,735)​$(48,019)
Issuance of common stock upon release of restricted stock units, net of tax withholdings​10,412​​—​​(14)​​—​​(14)
Stock-based compensation expense—​​—​​1,356​​—​1,356
Net loss—​​—​​—​​(22,826)​(22,826)
Balances, June 30, 202536,193,479​$362​$280,696​$(350,561)​$(69,503)
​​​​​​​​​​​​​​​
​​​​​​​​​​​​​​​
​​Stockholders’ Deficit
​​Common Stock​​​​​​​​​
​​​​​​​Additional​​​Total
​​​​​​​Paid-in​Accumulated​Stockholders’
​​Shares​ ​ ​Amount​ ​ ​Capital​ ​ ​Deficit​ ​ ​Deficit
Balances, December 31, 202536,431,444​$364​$282,574​$(501,534)​$(218,596)
2026 Debt and Warrant Amendments (Note 8)​—​​—​​20,640​​—​​20,640
Exercise of stock options​364,725​​4​​1,208​​—​​1,212
Issuance of common stock upon release of restricted stock units, net of tax withholdings​11,551​​—​​(63)​​​​​(63)
Issuance of common stock under ATM, net​338,000​​3​​2,370​​​​​2,373
Stock-based compensation expense​—​​—​​4,466​​—​​4,466
Net loss—​​—​​—​​(41,205)​​(41,205)
Balances, June 30, 202637,145,720​$371​$311,195​$(542,739)​$(231,173)
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.